The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Burden of cancer in metastatic renal cell carcinoma (mRCC).
 
Dena Battle
No Relationships to Disclose
 
Meghan Griffith
No Relationships to Disclose
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Sarah Psutka
Leadership - Janssen
Honoraria - AstraZeneca
Consulting or Advisory Role - CG Oncology; ImmunityBio; Janssen; Merck
Research Funding - Janssen; Steba Biotech
Travel, Accommodations, Expenses - medtronic
 
Ulka Vaishampayan
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Janssen Oncology; Merck Serono; Mural; Pfizer; Pfizer/Astellas; Sumitomo Pharma Oncology
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; Mashup Media; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Sanofi/Aventis; Seagen; Xencor
Research Funding - ALX Oncology (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); OncoC4; Pfizer (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Bayer
Other Relationship - ASCO; Kidney Cancer Association; KidneyCan; Myrovlytis Trust; Winn Foundation
 
Michael Staehler
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EMD Serono; EUSA Pharma; Exelixis; Incyte; Ipsen; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Apogepha; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Exelixis; Ipsen; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Oncorena; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pfizer